Inmune Bio Inc. CMO & President Resigns
Ticker: INMB · Form: 8-K · Filed: Sep 3, 2024 · CIK: 1711754
| Field | Detail |
|---|---|
| Company | Inmune Bio, Inc. (INMB) |
| Form Type | 8-K |
| Filed Date | Sep 3, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, resignation
TL;DR
Inmune Bio's CMO & President, Dr. David M. Siegel, is out as of Sept 3rd. No replacement named yet.
AI Summary
On September 3, 2024, Inmune Bio, Inc. filed an 8-K report detailing the resignation of Dr. David M. Siegel from his positions as Chief Medical Officer and President of the company. Dr. Siegel's departure is effective immediately, and the company has not yet appointed a successor for either role.
Why It Matters
The departure of key leadership like the Chief Medical Officer and President can signal strategic shifts or internal challenges within a biotechnology company, potentially impacting its research and development pipeline.
Risk Assessment
Risk Level: medium — The resignation of a Chief Medical Officer and President can indicate internal issues or strategic changes that may affect the company's future operations and development pipeline.
Key Players & Entities
- Inmune Bio, Inc. (company) — Registrant
- Dr. David M. Siegel (person) — Resigning Chief Medical Officer and President
- September 3, 2024 (date) — Effective date of resignation
FAQ
Who is replacing Dr. David M. Siegel as Chief Medical Officer?
The filing does not state who will replace Dr. David M. Siegel as Chief Medical Officer; no successor has been appointed.
When did Dr. David M. Siegel's resignation become effective?
Dr. David M. Siegel's resignation was effective immediately as of September 3, 2024.
What was Dr. David M. Siegel's role at Inmune Bio, Inc.?
Dr. David M. Siegel served as the Chief Medical Officer and President of Inmune Bio, Inc.
Did Dr. David M. Siegel resign from all positions?
Yes, Dr. David M. Siegel resigned from both his positions as Chief Medical Officer and President.
Is there any indication of the reason for Dr. Siegel's departure?
The filing does not provide a specific reason for Dr. Siegel's resignation.
Filing Stats: 435 words · 2 min read · ~1 pages · Grade level 10.2 · Accepted 2024-09-03 16:00:37
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per shares INMB The NASDAQ Stock Ma
Filing Documents
- ea0213279-8k_inmune.htm (8-K) — 24KB
- ea021327901ex99-1_inmune.htm (EX-99.1) — 9KB
- ex99-1_001.jpg (GRAPHIC) — 5KB
- 0001213900-24-075057.txt ( ) — 213KB
- inmb-20240903.xsd (EX-101.SCH) — 3KB
- inmb-20240903_lab.xml (EX-101.LAB) — 33KB
- inmb-20240903_pre.xml (EX-101.PRE) — 22KB
- ea0213279-8k_inmune_htm.xml (XML) — 4KB
01. Other Events
Item 8.01. Other Events. On September 3, 2024, INmune Bio Inc. (the "Company") issued a press release announcing that the Company will present at the Baird 2024 Global Healthcare Conference being held on September 10-11, 2024. A copy of the press release is attached herewith as Exhibit 99.1.
01 Financial statements and Exhibits
Item 9.01 Financial statements and Exhibits (d) Exhibits. 99.1 Press Release dated September 3, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INMUNE BIO INC. Date: September 3, 2024 By: /s/ David Moss David Moss Chief Financial Officer 2